Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...